|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer 显示文摘 | Souglakos J Philips J Wang R | 2009 | Br J Cancer2009，101，3： | 1 |
| 2 | Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase Ⅱ study显示文摘 | Kakolyris S Souglakos J Polyzos A | 2008 | Oncology2008，74，12： | 1 |
| 3 | Randomised phase-II trial of CAPIRI(capecitabine,irinotecan)plus bevacizumab vs FOLFIRI(folinic acid,5-fluorouracil,irinotecan)plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer(mCRC)显示文摘 | Souglakos J Ziras N Kakolyris S | 2012 | Br J Cancer2012，106，45： | 1 |
| 4 | IGF-I and IGF-II in relation to colorectal cancer显示文摘 | Manousos O Souglakos J Bosetti C | 1999 | Int J Cancer1999，83，1： | 1 |
| 5 | Central nervous system relapse in patients with breast cancer is associated with advanced stages, with the presence of circulating occult tumor cells and with the HER2/neu status显示文摘 | Souglakos J Vamvakas L Apostolaki S | 2006 | Breast Cancer Res2006，8，4： | 1 |
| 6 | FOLFOXIRI (folinic acid,5-fluorouracil,oxaliplatin and irinotecan) vs FOLFIRI (folinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre randomised phase Ⅲ trial from the Hellenic Oncology Research Group (HORG)显示文摘 | Souglakos J Androulakis N Syrigos K | 2006 | Br J Cancer2006，94，： | 1 |
| 7 | FOLFOXIRI(folinic acid,5-fluorouracil,oxaliplatin and irinotecan) VS FOLFIRI (foiinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre andomised phase Ⅲtrial from the Hellenic Oncology Research Group (HORG)显示文摘 | Souglakos J Androulakis N Syrigos K | 2006 | Br J Cancer2006，94，6： | 1 |
| 8 | How close are we to customizing chemotherapy in early non-small cell lung cancer? 显示文摘 | Ioannidis G Georgoulias V Souglakos J | 2011 | Ther Adv Meal Oncol2011，3，4： | 1 |
| 9 | A dose escalation and pharmacokinetic study of the biweekly administration of paclitax- el, gemcitabine and oxaliplatin in patients with advanced solid tumors显示文摘 | Saridaki Z Pappas P Souglakos J | 2009 | Cancer Chemother Pharmacol2009，65，1： | 1 |
| 10 | Oxaliplatin in combination with infusional 5-fluorouracil and leucovorinevery 2 weeks as first-line treatment in patients with advanced colorectal cancer:A Phase II Study显示文摘 | Kouroussis C Souglakos J Kakolyris S | | 0，，01： | 1 |
| 11 | FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first- line treatment in metastatic colorectal cancer (MCC) : a multi- centre randomised phase Ⅲ trial from the Hellenic Oncology Research Group (HORG) 显示文摘 | Souglakos J Androulakis N Syrigos K | 2006 | Br J Cancer2006，94，6： | 1 |
| 12 | Multicenter dosefinding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer显示文摘 | Souglakos J Androulakis N Mavroudis D | 2003 | Int J Radiat Oneol Biol Phys2003，56，5： | 1 |
| 13 | IGF-Ⅰ and IGF-Ⅱ in relation to colorectal cancer显示文摘 | Manousos O Souglakos J Bosetti C | | 0，，01： | 1 |
| 14 | A phase Ⅰ clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors显示文摘 | S Kakolyris Ch Kouroussis J Souglakos | 2001 | Oncology2001，61，4： | 1 |
| 15 | Triplet combination with irinotecan plus oxaliplatin plus continuousinfusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer:a multicenter phase Ⅱ trial显示文摘 | Souglakos J Mavroudis D Kakolyris S | 2002 | J Clin Oncol2002，20，： | 1 |
| 16 | Oxaliplatin in Combination with infusional 5-fluorouracil and leueovorin every 2 weeks as first-line treatment in patients with advanced Colorectal Cancer: A phase Ⅱ Study显示文摘 | Kouroussis C Souglakos J Kakolyris S | 2001 | Oncology2001，61，1： | 1 |
| 17 | Randomised phase-Ⅱ trial of CAPIRI(capecitabine,irinotecan)plus bevacizumab vs FOLFIRI(folinic acid,5-fluorouracil,irinotecan)plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer(mCRC)显示文摘 | SOUGLAKOS J ZIRAS N KAKOLYRIS S | 2012 | Br J Cancer2012，106，3： | 1 |
| 18 | Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine显示文摘 | Souglakos J Boukovinas I Taxon M | 2008 | Br J Cancer2008，98，10： | 1 |
| 19 | FOLFOXIRI ( folinic acid, 5 - fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5 -fluoranracil and irinotecan) as first- line treatment in metastatic colorectal cancer (MCC) : a muhicentre randomised phase Ⅲ trial from the Hellenic Oncology Research Group (HORG) 显示文摘 | SOUGLAKOS J ANDROULAKIS N SYRIGOS K | 2006 | Br J Cancer2006，94，6： | 1 |
| 20 | FOLFOXIRI (folinic acid,5-fluorouracil,oxaliplatin and irinotecan) vs FOLFIRI (folinic acid,5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC):a multicentre randomised phase Ⅲ trial from the Hellenic Oncology Research Group (HORG)显示文摘 | Souglakos J Androulakis N Syrigos K | 2006 | Br J Cancer2006，94，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员